Oruka Therapeutics’ (ORKA) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report released on Monday,Benzinga reports. Guggenheim currently has a $125.00 price target on the stock.

A number of other brokerages have also issued reports on ORKA. Barclays raised their target price on shares of Oruka Therapeutics from $50.00 to $78.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 7th. Stifel Nicolaus raised their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. BTIG Research raised their target price on shares of Oruka Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Finally, Leerink Partners raised their target price on shares of Oruka Therapeutics from $58.00 to $86.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $74.90.

Oruka Therapeutics Trading Up 3.0%

ORKA stock opened at $61.38 on Monday. Oruka Therapeutics has a twelve month low of $7.62 and a twelve month high of $64.61. The company’s 50 day moving average is $40.07 and its two-hundred day moving average is $32.63. The stock has a market cap of $3.04 billion, a P/E ratio of -33.00 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. On average, equities research analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the sale, the insider owned 33,377 shares of the company’s stock, valued at approximately $1,365,453.07. This trade represents a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 23,765 shares of company stock valued at $849,575. 24.69% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the second quarter valued at $28,000. BNP Paribas Financial Markets raised its stake in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the 4th quarter worth $37,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth $39,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.